P Libby, J Plutzky - The American Journal of Cardiology, 2007 - Elsevier Patients with type 2 diabetes mellitus and/or the metabolic syndrome have considerable cardiovascular
risk. Treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and
with antihypertensive and some antihyperglycemic agents reduces this risk, but residual ... Cited by 60 - Related articles - All 32 versions
C Fiévet, JC Fruchart, B Staels - Current Opinion in Pharmacology, 2006 - Elsevier The discovery of the crucial role of peroxisome proliferator-activated receptors (PPARs) as regulators
of lipid and glucose metabolism has raised interest in the development of synthetic ligands as
potential tools for therapeutic intervention in type 2 diabetes and the metabolic syndrome. ... Cited by 56 - Related articles - All 2 versions
P Balakumar, M Rose, SS Ganti, P Krishan, M … - Pharmacological Research, 2007 - Elsevier Cardiovascular disorders are the major cause of mortality in patients of diabetes mellitus. Peroxisome
proliferator activated receptors (PPARs) are ligand-activated transcription factors of nuclear hormone
receptor superfamily comprising of three subtypes such as PPARα, PPARγ and PPARδ/β. ... Cited by 49 - Related articles - All 3 versions
B Pourcet, JC Fruchart, B Staels, C … - Expert Opin. Emerging …, 2006 - informahealthcare.com More than 70% of patients with Type 2 diabetes mellitus (T2DM) die because of cardiovascular
diseases. Current therapeutic strategies are based on separate treatment of insulin resistance
and dyslipidaemia. Development of drugs with multimodal activities should improve ... Cited by 40 - Related articles - BL Direct - All 6 versions
F Chang, LA Jaber, HD Berlie, MB O … - Annals of …, 2007 - Harvey Whitney Books Author information provided at the end of the text. ... The Annals of Pharmacotherapy I 2007
June, Volume 41 I ... OBJECTIVE : To discuss the evolution of peroxisome proliferator-activated
receptor (PPAR) agonists from single site to multiple subtype or partial agonists for the ... Cited by 36 - Related articles - BL Direct - All 6 versions
BJ Goldstein, J Rosenstock, D Anzalone, … - Current Medical …, 2006 - informahealthcare.com Objective: The Glucose and Lipid Assessment in Diabetes (GLAD) trial examined the dose-response
relationship of the dual peroxisome proliferator- activated receptor (PPAR) α/γ agonist tesaglitazar
in type 2 diabetic patients. Study design: GLAD was a 12-week, multicenter, international, ... Cited by 29 - Related articles - BL Direct - All 4 versions
Q Qiao, W Gao, L Zhang, R Nyamdorj, J … - Annals of clinical …, 2007 - acb.rsmjournals.com Addresses 1 Department of the Public Health, University of Helsinki, PL41, Mannerheimintie
172, FIN-00014 Helsinki; 2 Diabetes and Genetic Epidemiology Unit, National Public Health
Institute, Helsinki; 3 South Ostrobothnia Central Hospital, Seinäjoki, Finland Cited by 28 - Related articles - BL Direct - All 7 versions
CE Quinn, PK Hamilton, CJ Lockhart, … - British Journal of …, 2008 - pubmedcentral.nih.gov Thiazolidinediones (TZDs) have been used for the treatment of hyperglycaemia in type 2 diabetes
for the past 10 years. They may delay the development of type 2 diabetes in individuals at high
risk of developing the condition, and have been shown to have potentially beneficial ... Cited by 21 - Related articles - BL Direct - All 4 versions
F Biscetti, E Gaetani, A Flex, T Aprahamian, T Hopkins, … - Diabetes, 2008 - Am Diabetes Assoc RESULTS—Activation of PPARα and PPARγ leads to endothelial tube formation in an
endothelial/interstitial cell co-culture assay. This effect is associated with increased production
of the angiogenic cytokine vascular endothelial growth factor (VEGF). Neovascularization ... Cited by 18 - Related articles - BL Direct - All 3 versions
- ►nursing2008.com E Mannucci, M Monami, C Lamanna, GF … - Diabetes, Obesity and …, 2008 - pt.wkhealth.com Aim: The aim of this meta-analysis of randomized clinical trials (RCT) was to assess whether
pioglitazone is also associated with increased cardiovascular risk, as recently reported for
rosiglitazone. Methods: RCT of pioglitazone were retrieved from Medline (any date up to ... Cited by 14 - Related articles - All 6 versions
